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Abstract
Background: The current treatment regimen for glioma patients is surgery, followed by radiation therapy plus
temozolomide (TMZ), followed by 6 months of adjuvant TMZ. Despite this aggressive treatment regimen, the
overall survival of all surgically treated GBM patients remains dismal, and additional or different therapies are
required. Depending on the cancer type, SPARC has been proposed both as a therapeutic target and as a
therapeutic agent. In glioma, SPARC promotes invasion via upregulation of the p38 MAPK/MAPKAPK2/HSP27
signaling pathway, and promotes tumor cell survival by upregulating pAKT. As HSP27 and AKT interact to regulate
the activity of each other, we determined whether inhibition of HSP27 was better than targeting SPARC as a
therapeutic approach to inhibit both SPARC-induced glioma cell invasion and survival.
Results: Our studies found the following. 1) SPARC increases the expression of tumor cell pro-survival and pro-death
protein signaling in balance, and, as a net result, tumor cell survival remains unchanged. 2) Suppressing SPARC
increases tumor cell survival, indicating it is not a good therapeutic target. 3) Suppressing HSP27 decreases tumor cell
survival in all gliomas, but is more effective in SPARC-expressing tumor cells due to the removal of HSP27 inhibition of
SPARC-induced pro-apoptotic signaling. 4) Suppressing total AKT1/2 paradoxically enhanced tumor cell survival,
indicating that AKT1 or 2 are poor therapeutic targets. 5) However, inhibiting pAKT suppresses tumor cell survival. 6)
Inhibiting both HSP27 and pAKT synergistically decreases tumor cell survival. 7) There appears to be a complex
feedback system between SPARC, HSP27, and AKT. 8) This interaction is likely influenced by PTEN status. With respect to
chemosensitization, we found the following. 1) SPARC enhances pro-apoptotic signaling in cells exposed to TMZ. 2)
Despite this enhanced signaling, SPARC protects cells against TMZ. 3) This protection can be reduced by inhibiting
pAKT. 4) Combined inhibition of HSP27 and pAKT is more effective than TMZ treatment alone.
Conclusions: We conclude that inhibition of HSP27 alone, or in combination with pAKT inhibitor IV, may be an
effective therapeutic approach to inhibit SPARC-induced glioma cell invasion and survival in SPARC-positive/PTEN-
wildtype and SPARC-positive/PTEN-null tumors, respectively.
Keywords: Glioma, SPARC, HSP27, AKT, Tumor cell survival, Apoptosis, Autophagy, Temozolomide
Background
Glioblastomas (GBMs) are the most malignant and het-
erogeneous human brain tumors [1]. Approximately
90%-95% of GBMs develop rapidly without evidence of
lower grade precursor tumors. These are designated as
primary or “de novo“ tumors [2]. The remaining 5%-10%
develop through progressive changes from low-grade
diffuse astrocytoma and/or anaplastic astrocytoma and
are designated as secondary GBMs [2]. Sequencing, copy
number analysis, and expression profiles have better
delineated the genetic alterations present in the tumors,
and permit an analysis of major signaling pathways dis-
rupted in primary GBMs [3,4]. Three major signaling
pathways are commonly disrupted. EGFR and PTEN
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mutation/deletion/methylation are the most common in
the RTK/RAS/PI3K signaling pathway, p53 mutation/
deletion in the p53 pathway, and CDKN2B mutation/
deletion in the RB pathway. Fewer secondary GBMs
have been analyzed as comprehensively; however, they
appear to share some of the same genetic defects as pri-
mary GBMs. One exception is IDH1, which is highly,
but not exclusively, mutated in secondary GBMs [4].
Gene expression profiling and integrated genomic ana-
lyses of a large number of tumors [5,6] have been pivo-
tal in defining subtypes of GBM that differ in their
genetic mutations and in their response to therapy [6].
The standard of care for newly diagnosed GBM
patients has been impacted by such analyses. Presently,
treatment includes surgery followed by treatment with
temozolomide (TMZ) plus radiotherapy followed by 6
months of adjuvant TMZ treatment [7,8]. This treat-
ment is most successful against tumors having a methy-
lated O6-methylguanine-DNA-methyltransferase
(MGMT) gene. The methylation silences the gene
thereby inhibiting the expression of an enzyme that
repairs TMZ-induced DNA damage, permitting
increased tumor cell death. This treatment regimen
increases progression-free survival at six months and
overall survival time to 14.6 months for selected patients
[9]; however, the median overall survival for all patients
operated for primary GBM ranges from 9.9 to 10.2
months [10]. Therefore, different or additional adjuvant
therapies are required.
Secreted protein acidic and rich in cysteine (SPARC
[11]), also known as osteonectin [12] and BM-40 [13], is
a matricellular protein that is expressed intracellularly
and is secreted into the extracellular matrix (ECM). It
functions, in part, to regulate levels of cell adhesion and
cell migration, as well as to regulate cell proliferation,
survival, and angiogenesis [14-16]. These functions are
important for normal development and for physiological
processes such as tissue remodeling during wound heal-
ing [14,15]. Its function is mediated, in part, through the
manipulation of integrin-ECM interactions [17,18],
which in turn can influence growth factor-induced sig-
naling cascades. Its function, therefore, is influenced by
the integrin expression profile of the cells, the ECM pre-
sent in the microenvironment, and the growth factor-
growth factor receptor status. As a consequence, its role
might differ between tissues or even from location to
location within a tissue, depending on the microenviron-
ment. This is important to consider because the role of
SPARC in cancer is somewhat controversial, as it posi-
tively correlates with invasion or worse prognosis for
some cancers, but negatively correlates with invasion or
worse prognosis for others [19]. As a result, it has been
regarded as a therapeutic target for pancreatic adenocar-
cinoma [20] and gastric cancer [21] on the one hand,
but as a therapeutic agent for colorectal [22,23] and
ovarian [24] cancers on the other. Indeed, in ovarian
cancer, SPARC has been shown to sensitize tumor cells
to cisplatin therapy [24] and to enhance apoptosis and
potentiate sensitivity to the chemotherapeutic agent 5-
fluorouracil in colorectal cancer [23]. In the latter, this
sensitivity was mediated by SPARC binding to procas-
pase 8.
We previously demonstrated that SPARC protein is
not immunohistochemically detectable in normal human
cerebral cortex but is highly expressed in human astro-
cytomas grades II-IV [25]. A subsequent study showed
SPARC to have restricted expression to the marginal
glia of the outer layer of the cortex, Bergmann glia in
the cerebellum, and an unidentified subpopulation of
cells in the subcortical white matter, and to be highly
expressed in all grades of astrocytomas [26].
We further demonstrated that SPARC promotes
tumor cell migration and invasion in vitro [27,28], and
we and others have demonstrated that SPARC promotes
invasion in vivo [29,30], suggesting that it is a therapeu-
tic target to prevent tumor invasion of gliomas. In addi-
tion, we have shown that SPARC expression decreases
glioma proliferation [29], and in this respect SPARC
expression is advantageous. Therefore, using SPARC as
a therapeutic target could result in the desired decrease
of tumor invasion, but might also result in an undesired
increase in tumor proliferation. We have therefore
investigated the signaling pathways induced by SPARC
to identify potential downstream therapeutic targets to
specifically inhibit SPARC-induced invasion, while main-
taining SPARC-mediated inhibition of proliferation.
We have found that SPARC promotes glioma migra-
tion and invasion, in part, through the upregulation of
the p38 MAPK-MAPKAPK2 (MK2)-HSP27 signaling
axis [28]. The small heat shock protein 27 (HSP27) con-
tributes to actin microfilament stabilization and reorga-
nization needed for cell migration [31,32]. These
functions are dependent upon its phosphorylation status
[31,32]. Indeed, we demonstrated that treatment of
SPARC-expressing glioma cells with HSP27 siRNA pre-
vented SPARC-induced migration and invasion [28].
Interestingly, SPARC also promotes glioma cell survi-
val under stressful conditions by upregulating AKT
activity [33]. The activation of AKT is thought to be
through the binding of SPARC to integrin beta 1 subu-
nit [17,18,34], and downstream activation of ILK [34].
Activated ILK activates AKT [35]. Indeed, suppression
of SPARC is accompanied by decreased ILK activity
[36].
In addition, HSP27 and AKT exist in complex with
p38 MAPK and MAPKAPK2 in the cytoplasm [37].
Activation of p38 MAPK results in the downstream acti-
vation of MAPKAPK2, which phosphorylates HSP27
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[37]. pHSP27 can bind to AKT and act as a scaffold
protein to permit the phosphorylation of AKT by MAP-
KAPK2 [38], leading to enhanced tumor cell survival
signaling by mTOR activation and downstream suppres-
sion of autophagy [39]. As SPARC can potentially pro-
mote AKT survival signaling through ILK and/or
HSP27, we hypothesized that HSP27 may serve as a
downstream target, not only to inhibit SPARC-induced
migration and invasion, but also to eliminate SPARC-
induced tumor cell survival signaling through AKT
activation.
HSP27 also plays a major role in inhibiting extrinsic
and intrinsic cell death pathways. It inhibits the extrinsic
apoptotic signaling pathway by preventing DAAX-
mediated signaling [40], and can prevent extrinsic and
intrinsic pathways by inhibiting the translocation of pro-
apoptotic tBID onto the mitochondrial membrane [40].
In addition, it can inhibit intrinsic apoptotic signaling by
binding to cytosolic cytochrome C and thereby prevent
the formation of the apoptosome and caspase 9 activa-
tion [41-45]. By interfering with caspase 3 activation, it
indirectly also limits caspase 7 activation [45]. Therefore,
the inhibition of HSP27 is expected to promote apopto-
tic signaling, as well as inhibit SPARC-induced tumor
cell survival signaling.
Consequently, the goals of this study were to deter-
mine 1) whether SPARC sensitized glioma cells to radia-
tion or chemotherapy, 2) whether targeting SPARC
decreased tumor cell survival, 3) whether HSP27 inhibi-
tion was a better target to suppress SPARC-induced
glioma cell survival, and 4) determine whether HSP27
inhibition suppressed SPARC-induced AKT activation
and survival. To this end, 1) control- and SPARC-
expressing U87 cells or LN443 cells treated with control
or SPARC siRNAs were untreated or subjected to TMZ
or radiation therapy (RT), and 2) control- and SPARC-
expressing U87 cells, LN443 cells, and human primary
glioma cell lines treated with control, HSP27, SPARC,
or AKT siRNAs or AKT inhibitor IV were subjected to
Western blot analyses to assess tumor cell survival and
death signaling, and were subjected to clonogenic assays
to determine whether the treatments affect tumor cell
survival and/or sensitize tumor cells to TMZ treatment.
Results
SPARC expression has no effect on glioma colony
forming efficiency or response to RT
The current treatment regimen for glioma patients
includes RT. If SPARC status affects RT outcome, this
would be important to know when considering targeting
SPARC or its downstream signaling molecules for ther-
apy. Therefore, clonogenic assays were used to evaluate
the effects of SPARC on RT using our previously
described U87 cells (low endogenous SPARC
expression) transfected with control GFP or SPARC-
GFP fusion protein [28] or LN443 cells (high endogen-
ous SPARC expression) transfected with control or
SPARC siRNA.
Fluorescence imaging showed that the surviving U87-
transfected colonies expressed either GFP (C1.1) or
SPARC-GFP (H2; Figure 1A). The clonogenic assay indi-
cated that enhancing SPARC expression in these cells
did not alter colony forming efficiency or alter survival
in response to RT (Figure 1B). In a complementary
experiment, suppressing SPARC expression in LN443
cells using SPARC siRNA also had no effect on the col-
ony forming efficiency or survival response to RT of
these cells (Figure 1C). Therefore, SPARC status does
not alter the effects of RT, suggesting it cannot be used
as a therapy to enhance radiation sensitivity.
Forced SPARC expression protects tumor cells against
TMZ
We then determined whether SPARC alters the surviv-
ing fraction of glioma cells treated with TMZ (Figure 2).
C1.1 GFP- and H2 SPARC-GFP-expressing glioma cells
were treated with increasing concentrations of TMZ for
2 days. Media were changed and the ability of cells to
form colonies was assessed by clonogenic assay. In
agreement with data in Figure 1, the colony forming
efficiencies of untreated control and SPARC-expressing
cells were similar (Figure 2A). For C1.1 control cells,
100 μM TMZ treatment severely reduced the surviving
fraction (100-fold). In contrast, the H2 SPARC-expres-
sing cells survived better, with 100 μM TMZ decreasing
the surviving fraction only 2.3-fold. Importantly, these
data indicate that SPARC-expressing tumor cells survive
better in TMZ (44-fold).
HSP27 inhibition suppresses survival more effectively in
SPARC-expressing cells
To determine whether targeting HSP27 had differential
effects in the absence or presence of SPARC, C1.1 GFP-
and H2 SPARC-GFP-expressing glioma cells were treated
with control or HSP27 siRNAs. The colony forming effi-
ciencies of both cell lines treated with control siRNA
were similar (Figure 2C). HSP27 siRNA suppressed the
colony forming efficiency of control cells (1.6-fold). How-
ever, treatment with HSP27 siRNA suppressed the colony
forming efficiency of SPARC-expressing cells even more
(4.2-fold; Figure 2C). These data suggest that inhibition
of HSP27 decreases tumor cell survival, and inhibition is
even more effective in SPARC-expressing cells.
Combined HSP27 inhibition and TMZ treatment is less
effective in SPARC-expressing cells
To determine whether HSP27 mediates SPARC-induced
survival in TMZ, C1.1 GFP- and H2 SPARC-GFP-
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expressing glioma cells were treated with control or
HSP27 siRNAs followed by treatment with increasing
concentrations of TMZ for 2 days. Media were changed
and the ability of cells to form colonies was assessed by
clonogenic assay (Figure 2D).
TMZ alone suppressed survival of the control siRNA-
treated SPARC-expressing cells approximately 2-fold (p
= 0.0004), while HSP27 inhibition plus 100 μM TMZ
only modestly suppressed the surviving fraction of the
SPARC-expressing cells a further 1.6-fold. TMZ alone
suppressed survival of the control siRNA-treated GFP-
expressing cells approximately 120-fold, while the inhi-
bition of HSP27 plus TMZ increased the sensitivity of
the control cells to lower doses (40-80 μM) of TMZ
(Figure 2D). These data indicate that HSP27 inhibition
sensitizes glioma cells to TMZ, but more so in the
absence of SPARC. Therefore despite the fact that
SPARC-expressing cells were more susceptible to
HSP27 inhibition alone, combined HSP27 siRNA and
TMZ was not as effective in these cells.
SPARC enhances the expression or activation of pro-
survival and pro-death proteins
To better understand the mechanism by which SPARC
promotes survival and protects cells against TMZ and
how HSP27 inhibition suppresses survival in the absence
Figure 1 SPARC does not enhance or suppress radiation therapy (RT). A. Representative fluorescent images of control C1.1 GFP- and H2
SPARC-GFP-expressing clonogenic colonies (×40 magnification). B. Average colony forming efficiency ± SD of untreated C1.1 and H2 cells (left
panel). Average surviving fraction ± SD of C1.1 and H2 cells exposed to 0 or 1-5 Gy (middle panel) or 0, 5 or 10 Gy (right panel), plating 3000
cells/60-mm dish. Plating 1000 cells/60-mm dish gave similar results. C. Average colony forming efficiency ± SD of untreated LN443 cells
transfected with control (Csi) or SPARC siRNA (SPARCsi) (left panel). Average surviving fraction ± SD of LN443 cells transfected with Csi or
SPARCsi exposed to 0, 5 or 10 Gy (right panel) plating 750 cells/60-mm dish. Plating 1500 cells/60-mm dish gave similar results.
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or presence of SPARC and/or TMZ, Western blots of
lysates from C1.1 GFP- and H2 SPARC-GFP-expressing
cells treated with control or HSP27 siRNAs were probed
for survival and death associated proteins. As TMZ has
been implicated in both apoptotic [46] and autophagic
[47] death in glioma cells, both mechanisms were inves-
tigated (Figure 3). An initial timing study was performed
to determine the effects of TMZ on control cells (see
Additional file 1: Figure S1). By days 6 and 8, no
increase in PARP cleavage was observed; however, TMZ
did induce autophagy, as detected by an increase in
LC3-II and increased p62 degradation, inferred by a
concomitant decrease in p-p62 (upper band) and
increased unphosphorylated p62 (lower band). These
data suggest that TMZ-induced autophagy is the major
death mechanism in these cells, at least at the time
points examined, and is likely responsible for the
approximate 120-fold decrease in the surviving fraction
observed for the Csi-treated C1.1 control cells treated
for 2 days with 100 μM TMZ (Figure 2D).
To determine whether SPARC alters survival and
death signaling, Westerns of lysates from control
siRNA-treated C1.1 GFP-expressing and the H2
SPARC-GFP-expressing cells were compared (0 vs. 0
TMZ; Figure 3A). The data show, as previously
reported, that SPARC-GFP promotes the upregulation
of endogenous SPARC [28], HSP27 [28], and pAKT
[33]. This increase in pro-survival proteins was accom-
panied by increased procaspase 8 and a less than 2-fold
increase in cleaved caspase 8, and by enhanced cleavage
of caspase 3 to p22 and p20 fragments. These changes
were accompanied by a very slight signal for cleaved
PARP (Figure 3A). SPARC had no effect on autophagy
based on LC3-II and p62 levels. Therefore, SPARC
Figure 2 Forced SPARC expression protects against temozolomide (TMZ) and suppresses the ability of HSP27 inhibition to sensitize
cells to lower concentrations of TMZ. A. Average colony forming efficiency ± SD of C1.1 and H2 plating 750 cells/60-mm dish. B. Average
surviving fraction ± SD of C1.1 GFP- and H2 SPARC-GFP-expressing cells in 0 (0.1% DMSO), 1, 10, or 100 μM TMZ plating 750 cells/60-mm dish.
TMZ (100 μM) suppressed survival of both clones relative to 0 drug; p ≤ 0.0048. However, SPARC-expressing cells survived better than control
cells in 100 μM TMZ; * p = 0.0022. Plating 375 and 1500 cells gave similar results. C. Average colony forming efficiency ± SD of C1.1 and H2 cells
transfected with control (Csi) or HSP27 siRNA (HSP27si), plating 750 cells/60-mm dish. *** p = 0.0001. D. Average surviving fraction ± SD of C1.1
and H2 cells transfected with Csi or HSP27si in the absence (0) or presence of increasing concentrations of TMZ, plating 750 cells/60-mm dish. *
H2 + Csi vs. H2 + HSP27si: 100 μM TMZ; p = 0.0020. ** C1.1 + Csi vs. C1.1 + HSP27si: 20 μM TMZ; p = 0.022, 40 μM TMZ; p = 0.0026, 60 μM and
80 μM TMZ; p = 0.0001. *** H2 + Csi vs. C1.1 + Csi: 20 μM TMZ; p = 0.015, 40-100 μM TMZ; p = 0.0001. **** H2 + HSP27si vs. C1.1 + HSP27si:
20-60 μM TMZ; p ≤ 0.0055, 80 μM and 100 μM TMZ; p = 0.0002. B, C. Plating 1500 cells gave similar results.
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regulates both pro-survival and pro-apoptotic proteins,
but their increases in expression appear to counterba-
lance one another as the C1.1 control GFP- and H2
SPARC-GFP-expressing cells treated with control siRNA
have similar colony forming efficiencies (Figure 2C and
see Additional file 2: Figure S2, Panel A for proposed
signaling mechanisms).
SPARC promotes apoptotic signaling in the presence of
TMZ
Interestingly, two days of TMZ treatment (80-100 μM)
slightly increased endogenous SPARC, pAKT, and
AKT1 levels in C1.1 control cells (Figure 3A and 3B);
however these effects were not observed in SPARC-
GFP-transfected cells (Figure 3A and 3C). Rather,
Figure 3 Forced SPARC enhances the expression or activation of pro-survival and pro-death proteins but promotes death signaling in
temozolomide (TMZ), whereas HSP27 inhibition promotes apoptotic signaling (SPARC-independent) and autophagic signaling (SPARC-
dependent), but suppresses autophagic signaling in the presence of TMZ and SPARC. A-D. Representative Western blots are illustrated for
n ≥ 3 experiments of C1.1 control GFP- or H2 SPARC-GFP-expressing cells treated with control siRNA (Csi) or HSP27 siRNA (HSP27si) for 72 hr.
Equal numbers of siRNA-treated cells were plated overnight in growth serum, and then treated with 0 (0.1% DMSO control), 40, 80 or 100 μM
TMZ for 2 days before lysing. Arrows indicate ≥ 2-fold increases or decreases due to ± SPARC expression and/or ± HSP27 siRNA treatment.
Arrow with brackets indicates 30% reduction. # - Indicates a ≥ 2-fold increase in the ratio of LC-3II/LC-3I. Asterisks indicate ≥ 2-fold increases or
decreases due to TMZ treatment.
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SPARC expression combined with increasing concentra-
tion of TMZ resulted in increasing caspase 7 and PARP
cleavage (Figure 3A, Figure 3C and see Additional file 2:
Figure S2, Panel A for proposed signaling mechanisms).
This increase in apoptotic signaling likely contributes to
the 2-fold decrease in the surviving fraction of the con-
trol siRNA (Csi)-treated SPARC-expressing cells with
100 μM TMZ (Figure 2D).
The slight increase in LC3-II in the H2 SPARC-GFP-
expressing cells (2.5-fold) compared to that in the GFP-
expressing cells (1.7-fold) likely does not contribute, as
no changes in expression were observed for p62. These
data suggest that the increases in LC3-II represent
initiation of TMZ-induced autophagy at this time point,
and that SPARC does not enhance autophagy.
Therefore, although SPARC expression enhanced pro-
apoptotic signaling after 2 days in TMZ, the Western
results combined with the clonogenic survival data sug-
gest that the SPARC-induced upregulation of the pro-
survival HSP27 and/or pAKT proteins may counter the
upregulation of the pro-death signals, thereby permitting
better survival in TMZ compared to the control cells.
HSP27 inhibition enhances apoptotic signaling
independently of forced SPARC, and enhances autophagic
signaling in the presence of forced SPARC
To determine whether the inhibition of HSP27 could
shift the balance of SPARC-induced signaling towards
increased death signaling, C1.1 control cells (Figure 3B)
and H2 SPARC-expressing cells (Figure 3C) were trea-
ted with control or HSP27 siRNAs.
As expected, no HSP27 signal was observed in control
cells treated with either control or HSP27 siRNAs due
to the very low level of endogenous HSP27 (Figure 3B;
0 vs. 0 TMZ). Despite this, HSP27 siRNA treatment was
accompanied by decreased AKT2, and a 30% decrease in
pAKT, suggesting that in control cells, the low level of
endogenous HSP27 (observed in long film exposures)
regulated pAKT activation. The loss of HSP27 did not
affect caspase 8, but was accompanied by caspase 3 clea-
vage to active p17 and p12 fragments, and increased
cleavage of caspase 7 and PARP. No changes were
observed in LC-3II/LC-3I ratio. Therefore, in the
absence of forced SPARC, HSP27 inhibition suppresses
survival signaling and induces apoptotic signaling.
In the H2 SPARC-expressing cells, HSP27 siRNA
treatment significantly reduced HSP27 as expected (Fig-
ure 3C; 0 vs. 0 TMZ). Of note, inhibition of HSP27 was
accompanied with suppressed levels of endogenous
SPARC and a decrease in AKT1 and 2 by 30% and 80%,
respectively. Despite a decrease in total AKT, pAKT
level was unchanged, suggesting that forced SPARC
maintained AKT phosphorylation. Similar to control
cells, the loss of HSP27 did not affect caspase 8, and
was accompanied by caspase 3 cleavage to active p17
and p12 fragments, and increased cleavage of both cas-
pase 7 and PARP. In contrast to the control cells,
HSP27 inhibition was accompanied by an increase in
LC-3II and a higher LC-3II/LC-3I ratio in the SPARC-
expressing cells. The induction of autophagy was also
supported by a decrease in p-p62 (upper band), suggest-
ing degradation of p-p62, and an increase in p62 (lower
band), suggesting synthesis of p62 to maintain
autophagy.
To assess the effects of HSP27 inhibition in the
absence versus the presence of forced SPARC expres-
sion, a direct comparison of control and SPARC-expres-
sing cells treated with HSP27 siRNA is illustrated
(Figure 3D). This comparison confirmed that SPARC
maintains elevated pAKT despite the greater than 2-fold
decreases in AKT1 and 2, that HSP27 inhibition induces
apoptosis independently of SPARC, and that autophagy
is enhanced in the presence of SPARC. These data sug-
gest that the further decrease in colony forming effi-
ciency in SPARC-expressing cells versus control cells
treated with HSP27 siRNA (Figure 2C) is due to
autophagy.
HSP27 inhibition combined with TMZ suppresses
autophagy in SPARC-expressing cells
The changes in apoptotic signaling induced by HSP27
siRNA were not altered by TMZ in either the control or
SPARC-expressing cells (Figure 3B, C, D and see Addi-
tional file 2: Figure S2, Panel B for proposed signaling
mechanisms). However, HSP27 inhibition combined
with TMZ treatment appears to suppress autophagy in
SPARC-expressing cells as evidenced by a decrease in
both p62 (lower band) and p-p62 (upper band; Figure
3C, D). These results suggest that the maintenance of
high pAKT by forced SPARC expression promotes the
survival in TMZ observed by the clonogenic assay (Fig-
ure 2D). We therefore determined whether inhibition of
AKT phosphorylation could sensitize the forced
SPARC-expressing cells to TMZ.
Suppression of pAKT signaling induces autophagic
signaling in control and SPARC-expressing cells in TMZ
AKT inhibitor IV was used to inhibit pAKT signaling in
C1.1 GFP- and H2 SPARC-GFP expressing cells in the
absence and presence of 100 μM TMZ (Figure 4). The
decrease in pPRAS40 confirmed the inhibition of pAKT
in control cells (Figure 4A). This pAKT suppression was
accompanied by increased autophagic signaling as
assessed by increased beclin and LC3-II, and a concomi-
tant decrease in p-p62 (upper band) and increase in p62
(lower band; Figure 4A). Inhibition of pAKT did not
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Figure 4 Inhibition of pAKT eliminates SPARC-induced survival in temozolomide (TMZ). A. Representative Western blots of C1.1 control
GFP- or H2 SPARC-GFP-expressing cells in the absence 0 (0.1% DMSO control) or presence of 100 μM TMZ ± AKT inhibitor IV at indicated
concentrations for 48 hr before lysing. Arrows indicate ≥ 2-fold increases or decreases due to ± TMZ treatment and asterisks indicate ≥ 2-fold
increases or decreases due to AKT inhibitor IV treatment. B. Means for surviving fraction ± SD of C1.1 or H2 cells treated ± AKT IV inhibitor ±
TMZ plating 1500 cells/60-mm dish are presented. For C1.1 * p = 0.0022, **, *** p = 0.0001. For H2 *,**,*** p = 0.0001. C. Means for surviving
fraction ± SD of C1.1 or H2 cells treated ± AKT IV inhibitor ± TMZ plating 1500 cells/60-mm dish are presented. * p = 0.014, ** p = 0.0006, *** p
≤ 0.0001, **** p ≤ 0.0003, ***** p ≤ 0.03 except H2 0.25 AKT inhibitor IV (40 vs. 80 ≤ μM TMZ) is not significant, ****** p ≤ 0.008. NS - not
significant. Plating 3000 cells gave similar results.
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induce apoptosis. TMZ alone was less effective at indu-
cing autophagic signaling, and had no effect on pAKT
inhibition.
In H2 SPARC-expressing cells, pAKT IV inhibition
decreased the level of pAKT, but was not as efficient at
inhibiting downstream signaling as the pPRAS40 levels
remained unchanged. As a result, 0.50 μM and 0.75 μM
AKT IV induced autophagy, but to a lesser degree. This
is likely due to forced SPARC expression maintaining a
higher level of pAKT in these cells. Despite this, the
inhibitor-induced autophagic signaling was still greater
than that observed in cells treated with TMZ alone, sug-
gesting that the inhibitor should eliminate SPARC-
induced survival in TMZ.
AKT IV inhibitor suppresses colony forming efficiency and
eliminates SPARC-induced survival in TMZ
In corresponding clonogenic assays, 0.5 μM AKT inhibi-
tor IV was able to suppress the colony forming effi-
ciency of both control and SPARC-expressing cells
(Figure 4B). The AKT IV inhibitor was as effective as
100 μM TMZ alone for control cells (Figure 4B, top
panel). Furthermore, the same concentration of inhibitor
eliminated the survival advantage of SPARC-expressing
cells in TMZ (Figure 4B, Bottom panel). To more accu-
rately assess the response of cells to TMZ after pAKT
inhibition, lower doses of AKT inhibitor IV were used
with lower doses of TMZ. AKT inhibitor IV did further
sensitize the cells to TMZ, and 0.25 μM AKT inhibitor
IV in combination with 80 μM TMZ was able to sup-
press the survival of SPARC-expressing tumor cells to
that observed for control cells treated with TMZ alone
(Figure 4C). These data suggest that SPARC-induced
upregulation of pAKT does lead to better survival in
TMZ.
The combined data thus far indicate that SPARC pro-
motes both pro-survival and pro-apoptotic signaling that
favors maintained survival. Inhibiting HSP27 is effective
in both control and SPARC-expressing cells by inducing
apoptosis in control cells and apoptosis and autophagy
in SPARC-expressing cells. Although SPARC induces
apoptotic signaling in TMZ, its induced pro-survival sig-
naling predominates to protect cells against temozolo-
mide. This protection can be removed by suppressing
SPARC-induced upregulation of pAKT activity.
It is interesting to note that forced SPARC expression
increases HSP27 and pAKT (Figure 3A), but the inhibi-
tion of HSP27 suppressed SPARC and pAKT in the
C1.1 control cells (Figure 3B), and endogenous SPARC
in the H2 cells (Figure 3C). This suggests that HSP27
and SPARC have the potential to regulate each other,
but this regulation is disrupted in the presence of forced
SPARC. To determine whether HSP27 regulates SPARC
and pAKT in the absence of forced SPARC, we
examined the effects of HSP27 inhibition on LN443
cells, which have high endogenous SPARC expression.
HSP27 inhibition in LN443 cells suppresses SPARC and
pAKT expression, promotes death signaling, decreases
colony forming efficiency, and increases sensitivity to
TMZ
LN443 glioma cells are highly resistant to TMZ treat-
ment (Additional file 3: Figure S3), and have high
SPARC, HSP27 and pAKT expression (Figure 5, Panel
A). We proposed that the inhibition of HSP27, in the
absence of forced SPARC, should suppress SPARC and
pAKT expression and induce death signaling. Further
we proposed that the presence of SPARC in LN443 con-
trol siRNA-treated cells should correlate with TMZ-
induced death signaling that would be eliminated by
HSP27 inhibition. Finally, we proposed that HSP27 inhi-
bition should decrease colony forming efficiency and
increase sensitivity to TMZ.
LN443 cells were treated with control and HSP27 siR-
NAs. As predicted, HSP27 siRNA treatment did sup-
press SPARC and pAKT levels, as well as decrease
caspase 8 cleavage (Figure 5A; left panel, 0 vs. 0 TMZ).
In addition, inhibition of HSP27 increased caspase 3,
caspase 7 and PARP cleavage. As the LC-3II/LC-3I was
slightly increased, likely due to suppression of pAKT,
the data suggest that both autophagy and apoptosis may
be induced by HSP27 inhibition in these cells. Indeed,
the colony forming efficiency was suppressed approxi-
mately 2.5 fold by HSP27 siRNA treatment (Figure 5B).
In agreement with the C1.1 and H2 data, high SPARC
expression in control siRNA-treated LN443 cells corre-
lated with increased caspase 7 and PARP cleavage, and
increased LC3-II in the presence of TMZ (Figure 5A;
left panel). Furthermore, this sensitivity to TMZ-induced
death signaling by SPARC was eliminated by treatment
with HSP27 siRNA (Figure 5A, left panel and see Addi-
tional file 2: Figure S2, Panel C for proposed signaling
mechanisms). The suppression of pAKT in LN443, as a
result of blocking HSP27, correlated with a 2-fold
increase in sensitivity to TMZ (Figure 5C).
Based on these data, we reasoned that the expression
profiles of control siRNA-treated LN443 cells (high
HSP27, high SPARC) versus the HSP27 siRNA-treated
LN443 cells (low HSP27, low SPARC) should be equiva-
lent to the expression profiles observed for control
siRNA-treated H2 cells (high HSP27, high SPARC) ver-
sus HSP27 siRNA-treated C1.1 cells (low HSP27, low
SPARC). Indeed, the results were similar (Figure 5A,
right panel), indicating that the results are not cell-line
specific.
Therefore, HSP27 inhibition is also efficient in indu-
cing death signaling in these glioma cells, and similar to
C1.1 cells (low SPARC, low pAKT) inhibition increased
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sensitivity to lower doses of TMZ. Unfortunately, this
experiment could not determine whether the decrease
in pAKT was directly due to inhibition of HSP27 or
consequential to HSP27 siRNA-induced suppression of
SPARC. Therefore, we next determined whether target-
ing SPARC would also produce the same results.
Inhibition of SPARC decreases apoptotic signaling and
eliminates sensitivity to TMZ in LN443 cells, but enhances
colony forming efficiency
To determine whether inhibition of SPARC would
mimic inhibition of HSP27, LN443 cells were similarly
subjected to control and SPARC siRNAs and the effects
on downstream signaling, colony forming efficiency, and
tumor cell survival in TMZ were similarly evaluated.
As expected, the loss of SPARC decreased procaspase
8, cleaved caspase 3 p22/20, and cleaved caspase 7,
which was accompanied by a lack of PARP cleavage
(Figure 6A). The inhibition of SPARC had no effect on
total HSP27, AKT, and pAKT, and was accompanied by
increased levels of pHSP27, supporting the contention
that SPARC is downstream of HSP27 signaling in these
cells, and that HSP27 and AKT induce survival (see
Additional file 2: Figure S2, Panel D for proposed
Figure 5 Inhibition of HSP27 in LN443 cells suppresses survival signaling, promotes death signaling, and decreases colony forming
efficiency, eliminates SPARC-induced pro-death signaling in temozolomide (TMZ), and decreases survival in TMZ. A. Representative
Western blots of LN443 cells (left panel) treated with control siRNA (Csi) or HSP27 siRNA (HSP27si) and H2 cells treated with control siRNA (Csi)
and C1.1 cells treated with HSP27 siRNA (HSP27si) (right panel) for 72 hr. For both panels, equal numbers of siRNA-treated cells were plated
overnight in growth serum, and then treated with 0 (0.1% DMSO control), 40, 80 or 100 μM TMZ for 2 days before lysing. Arrows indicate ≥ 2-
fold increases or decreases due to HSP27 siRNA treatment. # - Indicates a ≥ 2-fold increase in the ratio of LC-3II/LC-3I. Asterisks indicate ≥ 2-fold
increases or decreases due to TMZ treatment. Note: SPARC refers to endogenous SPARC in LN443 cells and SPARC-GFP in H2 cells, and 43/72
refers to the 43 kDa endogenous SPARC, whereas 72 kDa refers to SPARC-GFP. B. Means for colony forming efficiency ± SD of LN443 cells ±
HSP27 siRNA plating 750 cells/60-mm dish. *** p = 0.018. C. Means for surviving fraction ± SD of LN443 cells ± HSP27 siRNA ± increasing
concentrations of TMZ plating 750 cells/60-mm dish. * Csi vs. HSP27si: 20 μM; p = 0.0031, 40 μM; p = 0.0092, 60 μM; p = 0.0006, 80 μM; p =
0.0011, and 100 μM; p = 0.0053. Plating 1500 cells gave similar results.
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signaling mechanisms). The loss of SPARC and its
induced apoptotic signaling combined with the mainte-
nance of HSP27 and AKT pro-survival signaling shifted
the balance to increase survival as assessed by colony
forming efficiency (Figure 6B).
As previously demonstrated, SPARC expression was
associated with death signaling in TMZ, and SPARC
siRNA treatment suppressed this signaling (Figure 6A),
demonstrating that SPARC is indeed required for this
response. In agreement with the previous data, this
enhanced signaling in TMZ had little effect on cell sur-
vival in TMZ (Figure 6C).
That inhibition of SPARC had no effect on HSP27 or
pAKT in these cells supports the suggestion that HSP27
regulates SPARC and pAKT independently in these
cells. When SPARC is inhibited, HSP27 and pAKT inhi-
bit apoptosis and autophagy, and SPARC-induced death
signaling in TMZ is eliminated, resulting in greater sur-
vival of cells. These data indicate that SPARC is not a
good therapeutic target in these cells, and reinforces the
conclusion that SPARC is a poor chemosensitizer in
TMZ.
Suppression of total AKT1/2 enhances colony forming
efficiency and suppression of AKT1/2 or AKT3 reduces
SPARC-induced death signaling in TMZ
HSP27 inhibition suppressed pAKT in the absence of
SPARC in both the control C1.1 cells (Figure 3) and in
Figure 6 Inhibition of SPARC expression in LN443 suppresses pro-apoptotic signaling, increases colony forming efficiency, eliminates
SPARC-induced pro-death signaling in temozolomide (TMZ), and has no effect on survival in TMZ. A. Representative Western blots of
LN443 cells treated with control siRNA (Csi) or SPARC siRNA (SPARCsi) for 72 hr. Equal numbers of siRNA-treated cells were plated overnight in
growth serum, and then treated with 0 (0.1% DMSO control), or 40, 80 or 100 μM TMZ for 2 days before lysing. Arrows indicate ≥ 2-fold
increases or decreases due to SPARC siRNA treatment. Asterisks indicate ≥ 2-fold increases or decreases due to TMZ treatment. B. Means for
colony forming efficiency ± SD of LN443 ± SPARC siRNA plating 375 cells/60-mm dish. * p = 0.018. C. Means for surviving fraction ± SD of
LN443 ± SPARC siRNA ± increasing concentrations of TMZ plating 375 cells/60-mm dish. Plating 750 cells gave similar results.
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the LN443 cells (Figure 5), and this correlated with
increased apoptotic signaling. In addition, inhibition of
pAKT using inhibitor IV increased autophagy and
decreased clonogenic survival (Figure 4). These data
suggest that HSP27-induced activation of AKT contri-
butes to survival. However, inhibition of HSP27 affected
AKT1 and 2 differently than AKT3 depending on
SPARC status (Figure 3). We therefore separately exam-
ined the effects of control, AKT1/2 or AKT3 siRNAs on
downstream signaling, colony forming efficiency, and
survival in TMZ in the LN443 cells.
It was difficult to suppress total AKT1 and AKT2
more than 30% and 40%, respectively. This level of inhi-
bition did not suppress pAKT levels (Figure 7A), and so
the data were used to determine effects of reducing the
total AKT levels. This level of suppression did not affect
HSP27 or SPARC levels, suggesting the total AKT inhi-
bition effects are downstream of SPARC and HSP27.
Interestingly, the suppression of AKT1/2 had little effect
on autophagic signaling or PARP cleavage despite the
unanticipated decrease in caspase 3 cleavage (0 TMZ
Csi to 0 TMZ AKT1/2si, Figure 7A). This lack of death
signaling was accompanied by increased colony forming
efficiency (Figure 7C). This result was similar to that
observed when inhibiting SPARC, suggesting that
AKT1/2 may mediate this aspect of SPARC regulation
of survival. That SPARC and AKT1/2 may function
together in some as yet unknown mechanism is rein-
forced by the observation that suppression of AKT1/2
also reduced SPARC-induced death signaling in TMZ
(Figure 7A).
Similar signaling results were observed using AKT3
siRNA, which was very efficient at reducing AKT3 levels
(Figure 7B). While no changes were observed in colony
forming efficiency due to inhibition of AKT3 (Figure
7C), suppression of SPARC-induced death signaling in
TMZ was also observed (Figure 7B and see Additional
file 2: Figure S2, Panel E for proposed signaling mechan-
isms). These data suggest that the AKTs contribute to
SPARC-induced sensitivity to TMZ, and confirms that
this signaling has little effect, as assessed by the clono-
genic assay (Figure 7D).
Inhibition of pAKT decreases SPARC and increases
autophagy
It was surprising that a reduction in total AKTs did not
impact the level of pAKT. We therefore treated LN443
cells with AKT inhibitor IV to specifically assess the
effects of pAKT in the absence or presence of TMZ
(Figure 8). These results indicate that suppression of
pAKT suppressed SPARC. The suppression of SPARC
suggests that unlike total AKT, pAKT regulates SPARC
expression in these cells.
Inhibition of AKT activity correlated with decreased
caspase 3 cleavage, but increased caspase 7 cleavage.
Although suppression of pAKT did not induce PARP
cleavage after two days of treatment (Figure 8A), the
increase in cleaved caspase 7 by day 2 may contribute to
the slight delayed apoptosis observed by days four and
six (Figure 8D, and see Additional file 2: Figure S2,
Panel F for proposed signaling mechanisms).
As expected, the inhibitor induced autophagy in these
cells as indicated by decreased phospho- and total
PRAS40 by days 4 and 6 (Figure 8D), the increase in
LC3-II by day 2 (Figure 8A) and maintenance of high
LC3-II by days 4 and 6 with corresponding decrease on
p-p62 (upper band) and increased p62 (lower band) by
days 4 and 6 (Figure 8D). The suppression of pAKT and
induction of autophagy was accompanied by decreased
survival in the absence or presence of TMZ (Figure 8B).
TMZ did not alter the signaling observed with AKT
IV (Figure 8A). As the lowest dose of AKT inhibitor IV
was sufficient to induce death of all cells in the clono-
genic assay (Figure 8B), the ability of AKT inhibitor IV
to sensitize cells to TMZ treatment was studied using
lower doses of both agents. While increasing AKT inhi-
bitor IV correlated with decreasing surviving fraction,
AKT inhibitor IV did not further sensitize cells to TMZ
(Figure 8C). The data further demonstrate that 0.125
μM AKT inhibitor IV is more efficient than 80 μM
TMZ (Figure 8C).
The combined data for the LN443 cells indicate that
HSP27 regulates SPARC and pAKT in these cells, and
its suppression is accompanied by decreased survival
due to enhanced apoptosis and autophagy. However,
targeting SPARC alone is not a good therapeutic
approach as tumor cell survival is increased. Interest-
ingly, loss of SPARC due to HSP27 or pAKT inhibition
is not detrimental, suggesting that the death signaling
induced by HSP27 and pAKT inhibition takes
precedence.
In TMZ, the SPARC-induced death signaling is
impacted by a reduction in total AKTs, but survival in
TMZ is not suppressed and this correlates with the
maintenance of pAKT despite a decrease in total AKT.
Indeed inhibition of pAKT suppresses survival of cells
in the presence of TMZ.
Therefore, we have demonstrated that SPARC,
HSP27, and pAKT affect the expression and function
of each other. The data also indicate that, whether
SPARC expression is independent or dependent on
HSP27, HSP27 inhibition is effective in reducing the
survival of the cells. However, if SPARC expression is
independent of HSP27, pAKT will be high despite the
inhibition of HSP27, and the tumor cells will survive
better in TMZ.
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Inhibition of HSP27 decreases tumor cell survival in
primary glioma cells
These data were established using cell lines having high
SPARC expression and similar genetic backgrounds with
respect to PTEN and p53 status (see Additional file 4:
Table S1). As the majority of gliomas have high SPARC
expression, these data suggest that inhibition of HSP27
± pAKT may be useful therapeutic approaches. To
determine whether their inhibition would be useful for
primary brain tumors that may have different mutation
profiles, we selected two primary GBM-derived cell lines
having similar HSP27 and SPARC expression profiles,
Figure 7 Suppression of AKT1/2 or AKT3 decreases SPARC-induced pro-death signaling in temozolomide (TMZ); suppression of AKT1/
2 increases colony forming efficiency, and has no effect on survival in TMZ. A, B. Representative Western blots of LN443 cells treated with
control siRNA (Csi), AKT1/2 siRNA (AKT1/2si) or AKT 3 siRNA (AKT3si) for 72 hr. Equal numbers of siRNA-treated cells were plated overnight in
growth serum, and then treated with 0 (0.1% DMSO control), or 40, 80 or 100 μM TMZ (TMZ) for 2 days before lysing. Arrows indicate ≥ 2-fold
increases or decreases due to HSP27 siRNA treatment. Arrows with brackets indicate 30% and 40% reduction of AKT1 and AKT2, respectively. # -
Indicates a ≥ 2-fold increase in the ratio of LC-3II/LC-3I. Asterisks indicate ≥ 2-fold increases or decreases due to TMZ treatment. C. Means for
colony forming efficiency ± SD for LN443 cells ± AKT1/2 or AKT3 siRNA plating 750 cells. *** p ≤ 0.0003. D. Means for surviving fraction ± SD for
LN443 cells ± AKT1/2 or AKT3 siRNA ± increasing concentrations of TMZ plating 750 cells/60-mm dish.
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Figure 8 Suppression of pAKT in LN443 enhances autophagic signaling, and decreases survival of LN443 cells. A. Representative
Western of LN443 cells treated with 0 (0.1% DMSO) or 100 μM TMZ ± AKT inhibitor IV at the concentrations indicated for 2 days before lysing.
Arrows indicate ≥ 2-fold increases or decreases due to TMZ treatment. # - Indicates a ≥ 2-fold increase in the ratio of LC-3II/LC-3I. Asterisks
indicate ≥ 2-fold increases or decreases due to AKT inhibitor IV treatment. t = trend. B. Means for surviving fraction ± SD for LN443 cells ± AKT
inhibitor IV ± TMZ for 1500 cells/60-mm dish. * p = 0.0075. C. Means for surviving fraction ± SD for LN443 cells ± AKT inhibitor IV ± TMZ for
1500 cells/60-mm dish. *, ** p ≤ 0.0003, *** p = 0.03. Plating 3000 cells gave similar results. D. Representative Western of LN443 cells untreated
or treated with AKT inhibitor IV at the concentrations indicated for 2 days before lysing at days 4 or 6.
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but which differed in their PTEN, MGMT, and p53 sta-
tus (see Additional file 4: Table S1).
For HF373 tumor cells, HSP27 inhibition did not sup-
press SPARC or pAKT, suggesting that in this primary
cell line, SPARC expression was not under control of
HSP27 (Figure 9A). Similar to the H2 SPARC-GFP
expressing cells (Figure 3), HSP27 inhibition resulted in
increased pro-apoptotic (cleaved caspase 8, caspase 3,
caspase 7 and PARP) and pro-autophagic (increased
LC3-II and decreased p62) signaling, with maintenance
of pAKT levels (Figure 9A). Inhibition of HSP27 corre-
lated with decreased tumor cell survival in the clono-
genic assay (Figure 9B).
The HF373 cells are MGMT negative (Additional file
5: Figure S4), and thus are highly susceptible to TMZ
treatment (Figure 9C). As expected, TMZ treatment of
control siRNA-treated cells was associated with
increased pro-death signaling (Figure 9A), which was
eliminated by inhibition of HSP27 (Figure 9A), but as
also anticipated, HSP27 inhibition did not alter tumor
cell survival in TMZ.
In HF2303 tumor cells, inhibition of HSP27 did
decrease SPARC expression by 50%, but the decrease in
both SPARC and HSP27 was not sufficient to decrease
pAKT levels, suggesting additional pathways indepen-
dently governing pAKT expression in these cells. How-
ever, HSP27 inhibition was accompanied by increased
pro-apoptotic (cleaved caspase 3, caspase 7 and PARP),
but very low pro-autophagic (LC3-II and p62) signaling
(Figure 9A), likely due to the inhibition of autophagy by
the very high levels of pAKT. The increase in apoptotic
signaling combined with the lack of autophagy signaling
resulted in greater tumor cell survival in the clonogenic
assay (Figure 9B).
The HF2303 cells are MGMT-positive (Additional file
5: Figure S4), and are less responsive to TMZ treatment
(Figure 9D). As expected, the maintained high levels of
pAKT (Figure 9A) correlated with the inability of
HSP27 inhibition to suppress tumor cell survival in
TMZ (Figure 9D).
These data suggest that in primary human gliomas,
unlike LN433 cells, targeting HSP27 alone is not suffi-
cient to suppress SPARC and pAKT, and that other
genetic mutations may also play a role. We have pre-
viously demonstrated that PTEN is capable of suppres-
sing SPARC-induced pAKT [48]. An examination of the
PTEN status of the corresponding primary tumors,
available via TCGA website http://cancergenome.nih.
gov/, indicated that HF373 is likely PTEN wildtype
while HF2303 is PTEN mutant. These data suggest that
in HF373 cells, despite high SPARC expression, PTEN,
acting downstream of SPARC, can inhibit SPARC-
induced signaling to promote higher levels of pAKT.
Conversely, the combination of high SPARC and mutant
PTEN may super-induce pAKT. A direct comparison of
pAKT levels between the two cells lines (Figure 10A)
indicates that the pAKT levels are indeed higher in the
PTEN-mutant tumor cells. Therefore, in the HF2303
cells, HSP27 inhibition was insufficient to suppress the
elevated pAKT, which was likely enhanced by PTEN
loss.
Combined HSP27 inhibition and pAKT suppression
decreases tumor cell survival better than either alone
To determine whether inhibition of pAKT could aug-
ment suppression of HSP27 as a therapeutic approach,
HF2303 cells were treated with control or HSP27 siR-
NAs in combination with increasing amounts of AKT
inhibitor IV. Inhibition of pAKT alone induced
increased LC3-II along with a slight increase in cleaved
PARP. As with LN443 cells, induction of autophagy was
greater at day 4 (data not shown). HSP27 siRNA alone
induced apoptosis (cleaved PARP) and autophagy
(increased LC3-II and decreased p62) signaling. Indeed,
the combination treatment increased PARP cleavage
(Figure 10B). The 0.50 μM dose of AKT inhibitor IV
alone suppressed tumor cell survival (Figure 10C), and
sensitized cells to lower doses of TMZ (20 μM; Figure
10D). Importantly, the combination of HSP27 inhibition
plus 0.5 μM AKT inhibitor IV suppressed the surviving
fraction more than inhibition of HSP27 alone (Figure
10E), and was more effective than TMZ alone (Figure
10E).
The studies using the primary human glioma cells
lines indicate that in cells having high SPARC and
HSP27 but low pAKT, targeting HSP27 does suppress
survival by inducing apoptotic and autophagic signaling.
In cells with high SPARC, HSP27, and pAKT, inhibiting
HSP27 suppresses survival primarily through apoptotic
signaling, but combined HSP27 inhibition plus inhibi-
tion of pAKT better suppresses survival by inducing
apoptotic and autophagic signaling.
Discussion
The current treatment regimen for glioma patients is
surgery, followed by RT plus TMZ, followed by 6
months of adjuvant TMZ [7,8]. While this treatment
protocol has benefited a subpopulation of GBM patients
[9], the overall survival rate for the majority of primary
GBM patients is still less than 1 year [10]. Consequently,
additional or different therapies are required.
SPARC has been proposed both as a therapeutic target
and as a therapeutic agent. It is suggested that the
opposing designations may be due to cancer-type or
cell-type specific differences. In glioma, we previously
demonstrated that SPARC promotes invasion, but sup-
presses proliferation, suggesting that it may be a thera-
peutic target for invasion, but conversely, a therapy to
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inhibit proliferation (29). We also demonstrated that
SPARC increases total and pHSP27, which promotes
migration and invasion [28]. As SPARC can also
increase AKT phosphorylation, and as HSP27 and AKT
interact to regulate the activity of each other, we pro-
posed that inhibition of HSP27 may be a therapeutic
Figure 9 Inhibition of HSP27 suppresses survival but does not alter sensitivity to temozolomide (TMZ) in primary glioma cell lines. A.
Representative Western blots of HF373 and HF2303 cells treated with control siRNA (Csi) or HSP27 siRNA (HSP27si) for 72 hr. Equal numbers of
siRNA-treated cells were plated overnight in growth serum and then treated with TMZ at the concentrations indicated for 2 days before lysing.
Arrows indicate ≥ 2-fold increases or decreases due to siRNA treatment. # - Indicates a ≥ 2-fold increase in the ratio of LC-3II/LC-3I. Asterisks
indicate ≥ 2-fold increases or decreases due to TMZ treatment. t = trend. B. Means for colony forming efficiency ± SD for HF373 and HF2303
cells ± HSP27 siRNA for 3000 cells/60-mm dish. HF373 * p = 0.0006; HF2303 * p = 0.017. C, D. Means for surviving fraction ± SD for HF373 and
HF2303 cells treated with Control (Csi) or HSP27 (HSP27si) ± TMZ for 3000 cells/60-mm dish. Plating 1500 cells gave similar results.
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Figure 10 Inhibition of pAKT augments HSP27 siRNA suppression of survival but does not alter sensitivity to temozolomide (TMZ) in
primary glioma cell lines. A. Representative Western blots of HF373 and HF2303 cells grown in serum-free medium (SF DMEM) or treated with
control siRNA (Csi) or HSP27 siRNA (HSP27si) for 72 hr. B. Representative Western blots of HF2303 cells treated with control siRNA (Csi) or HSP27
siRNA (HSP27si) for 72 hr. Equal numbers of siRNA-treated cells were plated overnight in growth serum then treated ± AKT inhibitor IV at the
concentrations indicated for 2 days before lysing. Arrows indicate ≥ 2-fold increases or decreases due to siRNA treatment. # - Indicates a ≥ 2-fold
increase in the ratio of LC-3II/LC-3I. Asterisks indicate ≥ 2-fold increases or decreases due to AKT inhibitor IV treatment. C. Means for surviving
fraction ± SD for HF2303 cells treated with Control (Csi) or HSP27 (HSP27si) siRNAs ± AKT inhibitor IV plating 3000 cells/60-mm dish. * p =
0.0061, ** p = 0.0008. D. Means for surviving fraction ± SD for HF203 cells treated ± AKT inhibitor IV ± TMZ plating 3000 cells/60-mm dish. * p =
0.029. E. Means for colony forming efficiency ± SD for HF2303 cells treated with Csi or HSP27si siRNAs ± AKT inhibitor IV ± TMZ plating 3000
cells/60-mm dish. * p = 0.017, ** p = 0.0005, *** p = 0.0001, and **** 0.0012. Plating 6000 cells/60-mm dish gave similar results.
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approach to inhibit both SPARC-induced glioma cell
invasion and survival. Therefore, this study was underta-
ken to determine whether SPARC itself is a therapeutic
target or therapy to suppress glioma cell survival, to
determine whether HSP27 inhibition is a better thera-
peutic strategy to suppress SPARC-induced survival, and
to determine whether SPARC or HSP27 inhibition sen-
sitizes glioma cells to radiation treatment or TMZ
chemotherapy.
Two established cell line models were used, a forced
SPARC expression model (U87 cells transfected with
control GFP or SPARC-GFP fusion proteins) and an
unforced SPARC expression model (LN443 cells). These
cell lines are matched for PTEN (mutant) and p53
(wild-type) status. PTEN-mutant cell lines were chosen
as we previously demonstrated that PTEN reconstitution
suppresses pAKT even in the presence of forced SPARC
[48]. Neither upregulating SPARC in U87 cells nor sup-
pressing SPARC in LN443 cells had any effect on tumor
cell survival after radiation therapy (Figure 1). Therefore
the remainder of the study focused on the mechanisms
of SPARC-induced tumor cell survival ± TMZ treat-
ment, and the effects of SPARC, HSP27 or AKT or
pAKT inhibition ± TMZ on SPARC-induced survival,
using the above established cell lines and primary
human glioma cell lines.
Our studies found the following. 1) SPARC increases
the expression of pro-survival and pro-death protein sig-
naling in balance (Figure 3), and, as a net result, tumor
cell survival remains unchanged (Figure 2). 2) Suppres-
sing SPARC increases tumor cell survival, indicating it is
not a good therapeutic target (Figure 6). 3) Suppressing
HSP27 decreases tumor cell survival in all gliomas (Fig-
ures 2, 5, 9), but is more effective in SPARC-expressing
tumor cells due to the removal of HSP27 inhibition of
SPARC-induced pro-apoptotic signaling (Figures 3, 5, 9).
4) Suppressing total AKT1/2 paradoxically enhanced
tumor cell survival, indicating that AKT 1 or 2 are not
good therapeutic targets (Figure 7). 5) However, inhibit-
ing pAKT suppresses tumor cell survival (Figures 4, 8).
6) Inhibiting both HSP27 and pAKT synergistically
decreases tumor cell survival (Figure 10). 7) There
appears to be a complex feedback system between
SPARC, HSP27, and AKT (Figures 3, 5, 6). 8) This
interaction is likely influenced by PTEN status (Figure
10).
With respect to chemosensitization, we found the fol-
lowing. 1) SPARC does enhance pro-apoptotic signaling
in TMZ (Figure 3). 2) Despite this enhanced signaling,
SPARC protects cells against TMZ (Figures 2). 3) This
protection can be reduced by inhibiting pAKT (Figure
4). 4) Combined inhibition of HSP27 and pAKT is more
effective than TMZ treatment alone (Figure 10).
Our results shed some insight into the seemingly dis-
parate reports on the function of SPARC as a therapeu-
tic agent versus a therapeutic target. As noted, SPARC
increases invasion of glioma cells, but also has a sup-
pressive effect on their growth. This raised concerns
that the inhibition of SPARC itself would not be a suita-
ble therapeutic target, as suppression could lead to
increased proliferation. Indeed, our studies show that
inhibition of SPARC leads to increased tumor cell survi-
val. The mechanism for this is unknown, but may relate
to its ability to suppress cell cycle progression [15] and
the alleviation of this repression.
Looking at downstream SPARC-induced signaling
pathways, we surprisingly found that SPARC upregulates
both pro-survival and pro-death signaling proteins.
Indeed, independent analysis of one signaling pathway
versus the other would lead to different conclusions
regarding the use of SPARC as therapy or target. It was
interesting to find that the pro-survival signals directly
impede the pro-death signaling pathways (45). There-
fore, the final effect is that SPARC expression itself does
not alter the overall tumor cell survival. However, inhi-
bition of downstream survival signaling proteins HSP27
or pAKT undermines SPARC-induced survival signaling,
shifting the balance to increased death signaling. As
result, SPARC would be advantageous when suppressing
tumor cell survival with HSP27 or pAKT inhibition.
The data suggest a complex interaction and/or feed-
back system regarding these three proteins. SPARC can
upregulate HSP27 and pAKT. Inhibition of HSP27 sup-
presses pAKT and SPARC expression, and inhibition of
pAKT can suppress SPARC. In all cell lines examined
though, inhibition of HSP27 decreased survival.
It was surprising that HSP27 depletion could simulta-
neously decrease total AKT and increase pAKT levels.
This was not an artifact due to the inability to strip the
pAKT antibody from the membrane. In addition, total
AKT2 and AKT3 were probed independently of pAKT,
and total AKT2 was decreased. Therefore, the data sug-
gest that there is an unknown mechanism for decreasing
total AKT while maintaining high pAKT. Possibly this is
due to depletion of a specific AKT isoform, while phos-
phorylation of the remaining isoform(s) is detected.
Interestingly, this inverse relationship between total and
pAKT has been described in COS-7 cells undergoing
heat shock [49].
In addition, the extent of SPARC and pAKT suppres-
sion by HSP27 depletion is likely influenced by other
factors that can independently regulate pAKT, such as
the genetic background of the tumor cells with respect
to PTEN status. It is well established that the loss of
PTEN expression correlates with increased pAKT and
decreased patient survival [50,51]. Consequently, some
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gliomas may need to be targeted not only to suppress
HSP27 but also to suppress pAKT.
Using AKT as a therapeutic target has been a focus of
study for many cancers [52] including gliomas [53] due
to its pivotal role in regulating apoptosis and autophagy
[54,55]; however, its use is complicated by the fact that
there are three AKT isoforms (AKT1, AKT2, AKT3),
which are functionally distinct despite sharing a great
deal of sequence homology [56-59]. In addition, their
functions may differ in a cell-type specific manner. With
respect to brain tumors, the level of AKT1 found in
glioma cells and tissues was more similar to that found
in normal human astrocytes or non-neoplastic regions
of the brain [60]; whereas AKT2 levels were increased
[60,61], and AKT3 levels were decreased [60]. Interest-
ingly, AKT2 has been associated with suppression of
apoptosis and increased invasion, as blocking AKT2
induced apoptosis and decreased MMP2 and MMP9
[61,62].
In our cells, siRNA inhibition of AKT1/2 was partial
and resulted in increased tumor cell survival, while sup-
pression of AKT3 had no impact on tumor cell survival
in the clonogenic assay. Neither of the siRNA treat-
ments greatly affected apoptosis or autophagy signaling,
and this may be due to the inability to completely sup-
press pAKT using this approach. When cells were trea-
ted with an inhibitor of AKT, autophagy signaling was
significantly increased and tumor cell survival was sig-
nificantly decreased. These results emphasize the need
to assess effects not only on total AKT but also pAKT.
Our results suggest that the maintenance of pAKT in
the face of decreased total AKT could actually promote
tumor cell survival.
In our studies we used AKT inhibitor IV, which
blocks activation of AKT downstream of PI-3 K [53].
However, the different cell lines were differentially sensi-
tive to the inhibitor. When SPARC expression is forced,
the cells require higher concentrations of inhibitor to
suppress pAKT. In contrast, when SPARC is not forced,
inhibition of AKT suppressed pAKT and total AKT2.
While the suppression of pAKT was associated with
increased autophagic signaling, it had no affect on apop-
tosis. Interestingly, inhibition of pAKT decreased
SPARC and caspase-3, supporting the contention that
AKT can regulate SPARC expression.
The literature suggests that SPARC is a chemosensiti-
zer [22-24]. We therefore investigated the effects of
SPARC with respect to TMZ as it is the current che-
motherapy for glioma patients. We used concentrations
of TMZ up to 100 μM, which corresponds to serum
levels achieved in patients for treatment of gliomas [63].
The drug induces autophagy [47] and apoptosis [46,64].
However, the drug does not induce apoptosis in U87
cells after three days [46], but does so after prolonged
incubations of six [46] or eight days [64]. LN443 cells
are quite resistant, even at 100 μM for eight days [64],
and this may be because the drug is less effective at
inducing apoptosis in p53 wild-type glioma cells [64].
Therefore, to determine whether SPARC expression or
siRNA inhibition of HSP27 or AKTs enhanced the sen-
sitivity of these PTEN-mutant, p53 wild-type glioma
cells to TMZ, we treated the cells for 48 hr when no
effects from TMZ alone are observed.
When the SPARC-expressing glioma cells were treated
with TMZ, our results are consistent with previous
reports that suggest SPARC is a therapeutic agent. We
observed a SPARC-induced increase in procaspase 8,
cleaved caspase 8, cleaved caspase 7, and cleaved PARP
in the presence of TMZ. It is interesting to note that
caspase 8-induced apoptosis can be inhibited by procas-
pase 8/AKT/integrin beta 1 complex [65]. However,
SPARC may interfere with this anti-apoptotic complex
either by disrupting cell surface adhesion outside the
cell, and/or by binding to and activating procaspase 8
within the cell [23]. Activation of caspase 8 can activate
caspase 7, which in turn can cleave PARP [66,67]. These
data support our observations that SPARC siRNA
resulted in the loss of TMZ-associated death signaling
which was accompanied by decreased procaspase 8,
cleaved caspase 7 and cleaved PARP. Additionally AKT
1/2/3 inhibition served to decrease SPARC-induced
death signaling in TMZ. These combined observations
suggest that the mechanism involved is not chemother-
apy-specific, but SPARC-specific. However, despite
neither siRNA treatment resulting in the loss of this sig-
naling, inhibition of this pathway did not have a big
impact on tumor cell survival, also supporting the con-
clusion that SPARC is not a strong chemosensitizer.
In fact, the data suggest that despite SPARC-induced
death signaling, SPARC actually protects cells against
TMZ treatment. Furthermore, the data show that pAKT
mediates this effect, as AKT inhibition using AKT inhi-
bitor IV removes the survival advantage. HSP27 inhibi-
tion was also shown to suppress pAKT depending on
the cell line examined and whether SPARC expression
was forced or not. The data, however, suggest that other
genetic changes might influence the status of pAKT,
rendering it unregulatable by HSP27. For example, the
loss of PTEN, a common aberration in gliomas, results
in elevated pAKT. It is less clear as to whether PTEN
status influences the outcome of TMZ treatment, as
there are reports that wildtype PTEN correlates with
increased survival in the drug-treated patients [68-70]
and those demonstrating no benefit [71]. Additionally,
the outcome might be influenced by MGMT promoter
methylation status. Patients having tumors with PTEN-
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positive tumors with methylated MGMT had a survival
advantage when treated with TMZ plus erlotinib and
RT [72]. Further studies are needed.
The combined data using established cell lines indi-
cate that blocking HSP27 is an effective treatment
approach, but is more effective if SPARC expression is
forced (not regulated by HSP27) and promotes death
signaling. A major question is whether primary gliomas
have forced or non-forced SPARC expression. Two pri-
mary human glioma cell lines were treated with control
or HSP27 siRNA in the absence or presence of TMZ.
Treatment with HSP27 siRNA resulted in decreased col-
ony forming efficiency for both cell lines (Figure 9B).
However, the effects of HSP27 inhibition on signaling
were different between the cell lines (Figure 9A).
Inhibition of HSP27 in HF373 cells did not eliminate
SPARC suggesting a “forced SPARC” expression profile
as observed for the H2 cells. In contrast to the H2 cells
where high SPARC expression correlated with high
pAKT, pAKT remained low in the HF373 cells. As we
had previously demonstrated that PTEN reconstitution
could suppress SPARC-induced activation of AKT [48],
we considered the PTEN status for this cell line. No
mutation has yet been described for HF373, suggesting
a wildtype status. This suggests that wildtype PTEN sup-
presses SPARC-induced pAKT in these cells.
For HF2303 cells, inhibition of HSP27 only reduced
SPARC by 50% and pAKT remained high, also suggest-
ing a forced SPARC profile. In addition, PTEN is
mutant in HF2303. Therefore, SPARC expression com-
bined with loss of PTEN was sufficient to promote ele-
vated pAKT. Thus, the two cell lines had a “forced”
SPARC expression profile, but the resultant effect on
pAKT levels differed, likely due to differences in the
PTEN status.
As a consequence the loss of HSP27 promoted apop-
totic signaling in both cell lines. However, the HF373
cells (low pAKT) demonstrated increased autophagy,
whereas the HF2303 cells (high pAKT) did not. In the
latter cells, autophagy was induced with the AKT IV
inhibitor. These observations are in agreement with
observations that knockdown of AKT activity increases
autophagy, and apoptosis is not the prevailing response
[73]. Thus, we propose that HSP27 inhibition alone will
be most effective in SPARC-positive/PTEN-wildtype
tumors, while combined inhibition of HSP27 and pAKT
will likely be warranted for tumors that are SPARC-
positive/PTEN-null. Furthermore, this treatment is more
effective than treating with TMZ alone. As recent
reports indicate that TMZ and RT can produce a hyper-
mutation phenotype, affecting up to 30% of patients
[74], a treatment regimen that eliminates TMZ may be
highly advantageous. As HSP27 and AKT are already
the targets of clinical trials, the rationale for their use
has been established. Furthermore, inhibition of pHSP27
and/or AKT as a therapeutic approach has been pro-
posed for prostate and bladder cancer [75-77]. Studies
are therefore initiated to determine whether the strate-
gies demonstrated here will be successful in vivo to treat
gliomas.
Conclusions
We conclude that inhibition of HSP27 alone, or in com-
bination with pAKT inhibitor IV, may be valuable thera-
peutic approaches to inhibit SPARC-induced glioma cell
invasion and survival in SPARC-positive/PTEN-wildtype
or SPARC-positive/PTEN-null tumors, respectively.
Methods
Materials
Standard reagents were purchased from Fisher Scientific
(Hanover Park, IL) or VWR (West Chester, PA); others
as follow. Invitrogen Life Technologies (Carlsbad, CA):
Standard tissue culture reagents. ATCC (Manassas, VA):
U87MG and LN443 cells. Millipore (Bedford, MA):
Immobilon P membranes. Thermo Fisher (Rockford,
IL): ECL chemiluminescence kit. Denville Scientific
(Metuchen, NJ): High Blot CL autoradiography film.
BioRad: nonfat dry milk. Sigma-Aldrich (St. Louis, MO):
DMSO. LKT Laboratories, Inc. (St. Paul, MN): temozo-
lomide. Calbiochem/EMD Biosciences (San Diego, CA):
AKT Inhibitor IV (124011). siRNAs: Dharmacon (Lafay-
ette, CO): control siRNA (D001210-01), and human
HSP27 siRNA (HSPB1 L-005269-00-0010). Santa Cruz
Biotechnology (Santa Cruz, CA) SPARC siRNA (sc-
37166), AKT1/2 siRNA (sc-43609), and AKT3 siRNA
(sc-38911). Antibodies: Haematologic Technologies
(Essex Junction, VT): SPARC (AON-5031). Cell Signal-
ing Technology (Danvers, MA): phospho-HSP27 (Ser82;
2401), phospho-AKT (Ser473; 4501), AKT (9272), AKT1
(2938), AKT2 (2964), p62 (5114), caspase 7 (9492),
cleaved caspase 7 (9491), and PARP (9542). ImGenex
(San Diego, CA): caspase-8 (IMG-224A), and caspase-3
(IMG-144A and IMG145). Sigma-Aldrich (St. Louis,
MO): LC-3 (L7543). Santa Cruz Biotechnology (Santa
Cruz, CA): Goat anti-rabbit HRP secondary antibody,
goat anti-mouse HRP, donkey anti-goat HRP, HSP27
(sc-1049), Beclin 1 (sc-11427), actin (sc-1616) and
GAPDH (sc-20357). Millipore (Temecula, CA): AKT3
(07-383), pPRAS40 (07-1282), and PRAS40 (05-1070).
BD Pharmingen (San Diego, CA): MGMT (557045).
Cell lines and cell maintenance
The generation of the SPARC-GFP (H2) and control
GFP (C1.1) clones was previously described [28]. Cells
were maintained in DMEM + 10% FBS and geneticin
(400 μg/ml). LN443 was maintained in DMEM + 5%
FBS. Primary human cells were maintained in DMEM +
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10% FBS. All cells are maintained in 1% penicillin:strep-
tomycin (1:1). A summary of the cell lines used is pre-
sented in Additional file 4: Table S1.
Imaging
An Olympus 1 × 50 fluorescence microscope attached
to an Insight SPOT 4 camera was used to capture
images at × 40 magnification using SPOT software.
Composite Western images were prepared using Photo-
shop CS3 software.
Clonogenicity assays
Cells were trypsinized, counted with a hemocytometer,
and plated in triplicate at 375, 750, 1,000, 1500, 3,000 or
6,000 cells/60-mm tissue culture dish (as indicated in
figure legends), with media changes every 3-4 days.
After ~10 days for each experiment, colonies were
washed once with PBS, and then fixed in 100% metha-
nol for 20 min at -20°C. The cells were rinsed twice
with PBS, stained in 10% Giemsa for 10-15 min, and
then rinsed clean in distilled water. After drying, the
stained colonies having at least 50 cells were counted by
at least 2 individuals. The colony-forming efficiency
(CFE) was calculated as the number of colonies/number
of cells plated. The surviving fraction (SF) was calcu-
lated as the number of colonies/[(number of cells pla-
ted) (CFE of the control untreated cells)]. Representative
assays are illustrated for an n = 2 (RT) or n = 2 or 3 (±
TMZ ± siRNA) experiments.
For RT survival curves, the cells were plated as above,
allowed to attach for 24 hr, and then irradiated with 1-5
or 10 Gy. The control dishes were unexposed to radia-
tion, but otherwise handled the same. Radiation exposure
of cell cultures was performed using a 5000 Ci Cesium
(Cs-137) irradiator (Mark I; J. L. Shepherd and Associ-
ates, San Fernando, CA). The next day, media were chan-
ged, and the colonies were allowed to develop as above.
For TMZ treatment, cells were plated as above,
allowed to attach for 24 hr, and then treated with 0
(0.1% DMSO), 10, 20, 40, 60, 80, or 100 μM TMZ for 2
days. The media were then changed and the colonies
were allowed to develop as above.
For experiments incorporating control, HSP27,
SPARC, or AKT siRNAs, duplicate 60-mm dishes were
plated. After assessing the effectiveness of control and
gene-specific siRNA oligos, the oligos for HSP27 (240
nM), SPARC (120 nM), AKT1/2 (12.5 nM), or (AKT3
12.5 nM) were added for 72 hr. Cells were then trypsi-
nized and seeded into 60-mm dishes for the clonogenic
assay or 6-well plates for Western blot analyses. Cells
attached overnight, and were then treated with TMZ.
The drug was then removed, the cells rinsed, and fresh
media was added. Colonies were allowed to develop as
above. For experiments using AKT inhibitor IV, cells
were seeded into 60-mm dishes overnight, treated with
TMZ (40, 80 or 100 μM), AKT inhibitor IV (0.0625 -
1.0 μM), or both for 2, 4, 6, or 8 days for Western blot
analyses (see below). Controls were treated with 0.1%
DMSO for TMZ treatments or 0.01% DMSO for AKT
inhibitor IV treatments.
Dye exclusion assay
Dye exclusion assays were performed to ensure that
equal numbers of viable cells were plated.
Western blot analyses
To determine the effects of SPARC expression and
siRNA and/or AKT inhibitor IV ± TMZ treatment, cells
were plated (6-well plates) for protein lysates, as pre-
viously reported [23]. Protein concentration was deter-
mined using the BCA protein assay kit (Pierce,
Rockford, IL). Five to 25 μg of protein and 5-10 μl of
molecular weight marker were subjected to electrophor-
esis through 8%, 12.5% or 15% SDS-polyacrylamide
Tris-glycine gels and were transferred onto Immobilon
P membranes. Proteins were detected as previously
reported [23]. The primary antibodies were diluted
1:500 for caspase 3, caspase 8 and MGMT; 1:1000 for
HSP27, pHSP27, AKT, AKT1, AKT2, AKT3, pAKT,
PARP, caspase 7, cleaved caspase 7, LC-3, p62, pRAS40,
PRAS40, Beclin1, GAPDH; 1:6500 for SPARC, or 1:2000
for actin. Quantitation was performed using ImageJ soft-
ware as previously reported [23]. Representative Wes-
tern blots are illustrated for n ≥ 3 experiments.
Data and statistical analyses
Two-fold changes in protein levels were considered sig-
nificant, and the changes are indicated by asterisks (2-
fold increase or decrease due to TMZ treatment) or
arrows (2-fold increase or decrease due to SPARC
expression, or siRNA or AKT inhibitor IV treatment) in
the figures. For all statistical analyses the Student’s t-test
was performed. Statistical significance alpha was set at p
≤ 0.05.
Additional material
Additional file 1: Figure S1. Timing study of TMZ-induced death in
U87 cells. C1.1 GFP-expressing cells (1 × 104) were plated overnight in
6-well plates. Cells were treated with 0 (0.1% DMSO) or 100 μM TMZ for
2 days, and the media were changed every 2 days. Lysates were
harvested on days 6 and day 8. Western blots were probed as indicated.
Additional file 2: Figure S2. Proposed mechanisms. For all panels,
solid lines represent SPARC-induced pro-survival and pro-death signaling,
dashed lines represent siRNA or AKT inhibitor IV inhibition of signaling,
and changes in protein levels due to siRNA or AKT inhibitor IV inhibition
of signaling are indicated by changes in color intensity. Panel A.
Proposed mechanisms of forced SPARC-induced signaling in U87
glioma cells alone or treated with temozolomide (TMZ). In the
absence of TMZ, SPARC promotes migration via upregulation of the
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p38MAPK-MAPKAPK2-HSP27 signaling pathway [28]. SPARC promotes
pro-survival signaling (pHSP27, pAKT) and pro-apoptotic signaling (pro-
and cleaved caspase 8 and cleaved caspase 3). Note: pAKT indirectly
inhibits cleavage of caspase-3 through inhibition of caspase-9 activation.
The dashed blue lines illustrate caspase activation inhibited by HSP27.
We propose that the pro-survival and pro-apoptotic signaling cascades
balance one another, and cells survive. However, TMZ treatment of
SPARC-expressing cells induces caspase 7 and PARP activation as
indicated by the green line. Consistent with the literature [23], we
propose that integrin beta 1 recruits procaspase 8 and AKT. SPARC binds
to procaspase 8 to induce chemosensitivity to TMZ. Panel B. Inhibition
of HSP27 shifts the balance towards SPARC-induced pro-apoptotic
signaling. Dashed blue lines indicate that the loss of HSP27 expression
decreases migration and suppresses pro-survival signaling (AKT1, AKT2).
The dashed red lines indicate the resultant increase in pro-apoptotic
signaling (cleaved caspase 3, 7 and PARP), due to loss of HSP27, resulting
in increased apoptosis. Decreased AKT1/2 expression is accompanied by
the loss of SPARC-induced sensitivity to TMZ, indicated by the dashed
green line. Panel C. Proposed mechanism of endogenous SPARC-
regulated signaling in LN443 glioma cells treated with HSP27 siRNA
alone or with temozolomide (TMZ). SPARC signaling is proposed to be
the same as in U87 cells (Panel A). However, in the absence of forced
SPARC expression, HSP27 inhibition suppresses SPARC and pAKT, thereby
suppressing SPARC-induced pro-survival and pro-apoptotic signaling, as
indicated by the dashed red and blue lines. The loss of HSP27 inhibition
permits basal apoptotic signaling through caspase 3, 7 and PARP
cleavage. The loss of HSP27 is proposed to decrease migration. In TMZ,
the HSP27 inhibition suppresses SPARC-induced sensitivity through
caspase 7 and PARP activation, as indicated by the dashed green line.
Panel D. Proposed signaling in LN443 glioma treated with SPARC
siRNA alone or with TMZ. As expected, loss of SPARC eliminates
enhanced pro-survival signaling through HSP27 and pAKT and eliminates
pro-apoptotic signaling through caspases 8 and 3. Survival is maintained
through basal HSP27 and AKT signaling to inhibit apoptosis, as indicated
by the red lines. In TMZ, loss of SPARC eliminates caspase 7and PARP
cleavage, indicated by the dashed green line. Panel E. Proposed
signaling in LN443 glioma cells treated with AKT1/2/3 siRNA and
TMZ. AKT1/2 or AKT3 inhibition results in decreased total AKT1/2 or
AKT3, but not pAKT. We propose that SPARC-induced procaspase 8
expression and cleavage are not affected, permitting the cleavage of
caspase 3. However, SPARC-induced upregulation of HSP27 inhibits
further cleavage of caspases 3, 8 and PARP, as indicated by the red lines.
In TMZ, suppression of either AKT1/2 or AKT3 reduced SPARC-induced
cleavage of caspase 7 and PARP, as indicated by the dashed green line.
Panel F. Proposed signaling in LN443 glioma cells treated with AKT
inhibitor IV and TMZ. AKT inhibitor IV suppresses total AKT2, pAKT,
SPARC. Loss of pAKT and SPARC permits basal cleavage of caspase 3, but
basal levels of HSP27 inhibits further caspase 3 and 8 and PARP cleavage.
Unexpectedly, the inhibitor increased cleaved caspase 7 by in the
absence or presence of TMZ, but this did not enhance apoptosis.
Symbols are courtesy of SABiosciences.
Additional file 3: Figure S3. SPARC expression does not protect
LN443 cells against temozolomide (TMZ). Average surviving fraction ±
SD of LN443 cells in 0, 1, 50, and 100 μM TMZ plating 375 cells/60-mm
dish.
Additional file 4: Table S1. Summary of cell Lines.
Additional file 5: Figure S4. MGMT expression profile. Westem blot
analysis of MGMT protein in glioma lysates. X- empty lane. T98G is a
positive control for MGMT.
Abbreviations
RT: Radiation therapy; TMZ: Temozolomide; SPARC: Secreted protein acidic
and rich in cysteine.
Acknowledgements
The authors thank Dr. Christine Billecke for helpful discussions regarding the
clonogenic assays. We thank Dr. Ken Barton and Mr. Andrew Kolozsvary for
assistance with the radiation therapy, and Mr. Bradley Krasnick for assistance
with the clonogenic assays. We are grateful for the continued support of the
Barbara Jane Levy family. Supported in part by NIH/NCI grants CA86997 and
CA138401 (SAR).
Author details
1The Barbara Jane Levy Laboratory of Molecular Neuro-Oncology, Henry Ford
Hospital, 2799 West Grand Blvd., Detroit, MI 48202, USA. 2The William &
Karen Davidson Laboratory of Cell Signaling and Tumorigenesis, Hermelin
Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, 2799
West Grand Blvd., Detroit, MI 48202, USA. 3Department of Radiation
Oncology, Henry Ford Hospital, 2799 West Grand Blvd., Detroit, MI 48202,
USA.
Authors’ contributions
CRS performed radiation and clonogenic assays, AKT Inhibitor IV assays,
Western blot analyses, and participated in experimental design. WAG
performed siRNA inhibition experiments, clonogenic assays, and Western
blot analyses. DK performed clonogenic assays. SLB participated in
experimental design and execution of radiation assays, and interpreted
radiation data. CB critically reviewed data and manuscript. SAR conceived of
the overall study and design, performed Image J analyses, analyzed and
interpreted all data, wrote and submitted the manuscript. All authors read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 18 October 2011 Accepted: 5 April 2012
Published: 5 April 2012
References
1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A,
Scheithauer BW, Kleihues P: The 2007 WHO classification of tumours of
the central nervous system. Acta Neuropathol 2007, 114:97-109.
2. Ohgaki H, Kleihues P: Genetic pathways to primary and secondary
glioblastoma. Am J Pathol 2007, 170:1445-1453.
3. Cancer Genome Atlas Research Network: Comprehensive genomic
characterization defines human glioblastoma genes and core pathways.
Nature 2008, 455:1061-1068.
4. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P,
Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S,
Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J,
Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD,
Karchin R, Papadopoulos N, Parmigiani G, et al: An integrated genomic
analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
5. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A,
Holland E: Glioblastoma subclasses can be defined by activity among
signal transduction pathways and associated genomic alterations. PLoS
One 2009, 4:e7752.
6. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller R,
Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly M, Tamayo P,
Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG,
James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK,
Speed TP, Gray JW, Meyerson M, Getz G, The Cancer Genome Atlas
Research Network, et al: Integrated genomic analysis identifies clinically
relevant subtypes of glioblastoma characterized by abnormalities in
PDGFRA, IDH1, EGFR, and NF. Cancer Cell 2010, 17:98-110.
7. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ,
Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC,
Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E,
Mirimanoff RO, European Organisation for Research and Treatment of
Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of
Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant
temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
8. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M,
Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P,
Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R: MGMT gene silencing
and benefit from temozolomide in glioblastoma. N Engl J Med 2005,
352:997-1003.
Schultz et al. Molecular Cancer 2012, 11:20
http://www.molecular-cancer.com/content/11/1/20
Page 22 of 24
9. Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M: Six-
month progression-free survival as an alternative primary efficacy
endpoint to overall survival in newly diagnosed glioblastoma patients
receiving temozolomide. Neuro Oncol 2010, 3:274-382.
10. Helseth R, Helseth E, Johannesen TB, Langberg CW, Lote K, Rønning P,
Scheie D, Vik A, Meling TR: Overall survival, prognostic factors, and
repeated surgery in a consecutive series of 516 patients with
glioblastoma multiforme. Acta Neurol Scand 2010, 122:159-167.
11. Sage EH, Johnson C, Bornstein P: Characterization of a novel serum
albumin-binding glycoprotein secreted by endothelial cells in culture. J
Biol Chem 1984, 259:3993-4007.
12. Termine JD, Kleinman HK, Whitson SW, Conn KM, McGarvey ML, Martin GR:
Osteonectin, a bone-specific protein linking mineral to collagen. Cell
1981, 26:99-105.
13. Mann K, Deutzmann M, Paulsson R, Timpl R: Solubilization of protein BM-
40 from a basement membrane tumor with chelating agents and
evidence for its identity with osteonectin and SPARC. FEBS Lett 1987,
218:167-172.
14. Brekken RA, Sage EH: SPARC, a matricellular protein: at the crossroads of
cell-matrix communication. Matrix Biol 2001, 19:815-827.
15. Bornstein P, Sage EH: Matricellular proteins: extracellular modulators of
cell function. Curr Opin Cell Biol 2002, 14:608-616.
16. Tai IT, Tang MJ: SPARC in cancer biology: its role in cancer progression
and potential for therapy. Drug Resist Updat 2008, 11:231-246.
17. Barker TH, Baneyx G, Cardo-Vila M, Workman GA, Weaver M, Menon PM,
Dedhar S, Rempel SA, Arap W, Pasqualini R, Vogel V, Sage EH: SPARC
regulates cell-matrix interaction through direct binding to integrin-
linked kinase. J Biol Chem 2005, 280:36483-36493.
18. Nie J, Chang B, Traktuev DO, Sun J, March K, Chan L, Sage EH, Pasqualini R,
Arap W, Kolonin MG: IFATS collection: Combinatorial peptides identify
alpha5beta1 integrin as a receptor for the matricellular protein SPARC
on adipose stromal cells. Stem Cells 2008, 26:2735-2745.
19. Bos TJ, Cohn SL, Kleinman HK, Murphy-Ulrich JE, Podhajcer OL, Rempel SA,
Rich JN, Rutka JT, Sage EH, Thompson EW: International Hermelin brain
tumor symposium on matricellular proteins in normal and cancer cell-
matrix interactions. Meeting summary. Matrix Biol 2004, 23:64-70.
20. Miyoshi K, Sato N, Ohuchida K, Mizumoto K, Tanaka M: SPARC mRNA
expression as a prognostic marker for pancreatic adenocarcinoma
patients. Anticancer Res 2010, 30:867-871.
21. Zhao ZS, Wang YY, Chu YQ, Ye ZY, Tao HQ: SPARC is associated with
gastric cancer progression and poor survival of patients. Clin Cancer Res
2010, 16:260-268.
22. Taghizadeh F, Tang MJ, Tai IT: Synergism between vitamin D and
secreted protein acidic and rich in cysteine-induced apoptosis and
growth inhibition results in increased susceptibility of therapy-resistant
colorectal cancer cells to chemotherapy. Mol Cancer Ther 2007, 1:309-317.
23. Tang MJ, Tai IT: A novel interaction between procaspase 8 and SPARC
enhances apoptosis and potentiates chemotherapy sensitivity in
colorectal cancers. J Biol Chem 2007, 282:34457-34467.
24. Bull Phelps SL, Carbon J, Miller A, Castro-Rivera E, Arnold S, Brekken RA,
Lea JS: Secreted protein acidic and rich in cysteine as a regulator of
murine cancer growth and chemosensitivity. Am J Obstet Gynecol 2009,
200:180e1-180e7.
25. Rempel SA, Golembieski WA, Ge S, Lemke N, Elisevich K, Mikkelsen T,
Gutierrez JA: SPARC: a signal of astrocytic neoplastic transformation and
reactive response in human primary and xenograft gliomas. J
Neuropathol Exp Neurol 1998, 57:1112-1121.
26. Capper D, Mittelbronn M, Goeppert B, Meyermann R, Schittenhelm J:
Secreted protein, acidic and rich in cysteine (SPARC) expression in
astrocytic tumour cells negatively correlates with proliferation, while
vascular SPARC expression is associated with patient survival.
Neuropathol Appl Neurobiol 2010, 36:183-197.
27. Golembieski WA, Ge S, Nelson K, Mikkelsen T, Rempel SA: Increased SPARC
expression promotes U87 glioblastoma invasion in vitro. Int J Dev
Neurosci 1999, 17:463-472.
28. Golembieski W, Thomas SL, Schultz CR, Yunker CKH, Cazacu S, Barker T,
Sage EH, Brodie C, Rempel SA: HSP27 mediates SPARC-induced changes
in glioma morphology, migration and invasion. Glia 2008, 56:1061-1075.
29. Schultz C, Lemke N, Ge S, Golembieski WA, Rempel SA: Secreted protein
acidic and rich in cysteine promotes glioma invasion and delays tumor
growth in vivo. Cancer Res 2002, 62:6270-6277.
30. Rich JN, Shi Q, Hjelmeland M, Cummings TJ, Kuan CT, Bigner DD,
Counter CM, Wang XF: Bone-related genes expressed in advanced
malignancies induce invasion and metastasis in a genetically defined
human cancer model. J Biol Chem 2003, 278:15951-15957.
31. Guay J, Lambert H, Gingras-Breton G, Lavoie JN, Huot J, Landry J:
Regulation of actin filament dynamics by p38 map kinase-mediated
phosphorylation of heat shock protein 27. J Cell Sci 1997, 110:357-368.
32. McGregor E, Kempster L, Wait R, Gosling M, Dunn MJ, Powell JT: F-actin
capping (CapZ) and other contractile saphenous vein smooth muscle
proteins are altered by hemodynamic stress: a proteonomic approach.
Mol Cell Proteomics 2004, 3:115-124.
33. Shi Q, Bao S, Maxwell JA, Reese ED, Friedman HS, Bigner DD, Wang XF,
Rich JN: Secreted protein acidic, rich in cysteine (SPARC), mediates
cellular survival of gliomas through Akt activation. J Biol Chem 2004,
279:52200-52209.
34. Weaver MS, Workman G, Sage EH: The copper binding domain of SPARC
mediates cell survival in vitro via interaction with integrin β1 and
activation of integrin-linked kinase. J Biol Chem 2008, 283:22826-22837.
35. McDonald PC, Fielding AB, Dedhar S: Integrin-linked kinase-essential roles
in physiology and cancer biology. J Cell Sci 2008, 121:3121-3132.
36. Shi Q, Bao S, Song L, Wu Q, Bigner DD, Hjelmeland AB, Rich JN: Targeting
SPARC expression decreases glioma cellular survival and invasion
associated with reduced activities of FAK and ILK kinases. Oncogene
2007, 26:4084-4094.
37. Zheng C, Lin Z, Zhao ZJ, Yang Y, Niu H, Shen X: MAPK-activated protein
kinase-2 (MK2)-mediated formation and phosphorylation-regulated
dissociation of the signal complex consisting of p38, MK2, Akt, and
Hsp27. J Biol Chem 2006, 281:37215-37226.
38. Wu R, Kausar H, Johnson P, Montoya-Durango DE, Merchant M, Rane MJ:
Hsp27 regulates Akt activation and polymorphonuclear leukocyte
apoptosis by scaffolding MK2 to Akt signal complex. J Biol Chem 2007,
282:21598-21608.
39. Janku F, McConkey DJ, Hong DS, Kurzrock R: Autophagy as a target for
anticancer therapy. Nat Rev Clin Oncol 2011, 8:528-539.
40. Charette SJ, Lavoie JN, Lambert H, Landry J: Inhibition of Daxx-mediated
apoptosis by heat shock protein 27. Mol Cell Biol 2000, 20:7602-7612.
41. Paul C, Manero F, Gonin S, Kretz-Remy C, Virot S, Arrigo AP: Hsp27 as a
negative regulator of cytochrome C release. Mol Cell Biol 2002,
22:816-834.
42. Bruey JM, Ducasse C, Bonniaud P, Ravagnan L, Susin SA, Diaz-Latoud C,
Gurbuxani S, Arrigo AP, Kroemer G, Solary E, Garrido C: HSP27 negatively
regulates cell death by interacting with cytochrome c. Nat Cell Biol 2000,
2:645-652.
43. Garrido C, Bruey JM, Fromentin A, Hammann A, Arrigo AP, Solary E: HSP27
inhibits cytochrome c-dependent activation of procaspase-9. FASEB J
1999, 13:2061-2070.
44. Concannon CG, Orrenius S, Samali A: Hsp27 inhibits cytochrome c-
mediated caspase activation by sequestering both pro-caspase-3 and
cytochrome c. Gene Expr 2001, 9:195-201.
45. Arya R, Mallik M, Lakhotia SC: Heat shock genes- integrating cell survival
and death. J Biosci 2007, 32:595-610.
46. Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF, Kaina B:
Apoptosis in malignant glioma cells triggered by the temozolomide-
induced DNA lesion O6-methylguanine. Oncogene 2007, 26:186-197.
47. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S: Role of
autophagy in temozolomide-induced cytotoxicity for malignant glioma
cells. Cell Death Differ 2004, 11:448-457.
48. Thomas SL, Alam R, Lemke N, Schultz LR, Gutiérrez JA, Rempel SA: PTEN
augments SPARC suppression of proliferation and inhibits SPARC-
induced migration by suppressing SHC-RAF-ERK and AKT signaling.
Neuro Oncol 2010, 12:941-955.
49. Mo HJ, Lee HC, Choi HS, Yang SI: Heat shock-induced, caspase-3-
independent rapid breakdown of Akt and consequent alteration of its
total phosphorylation/activity level. Biochem Biophys Res Commun 2000,
276:702-706.
50. Ermoian RP, Furniss CS, Lamborn KR, Basila D, Berger MS, Gottschalk AR,
Nicholas MK, Stokoe D, Haas-Kogan DA: Dysregulation of PTEN and
protein kinase B is associated with glioma histology and patient
survival. Clin Cancer Res 2002, 8:1100-1106.
51. Wiencke JK, Zheng S, Jelluma N, Tihan T, Vandenberg S, Tamgüney T,
Baumber R, Parsons R, Lamborn KR, Berger MS, Wrensch MR, Haas-
Schultz et al. Molecular Cancer 2012, 11:20
http://www.molecular-cancer.com/content/11/1/20
Page 23 of 24
Kogan DA, Stokoe D: Methylation of the PTEN promoter defines low-
grade gliomas and secondary glioblastoma. Neuro Oncol 2007, 9:271-279.
52. Crowell JA, Steele VE, Fay JR: Targeting the AKT protein kinase for cancer
chemoprevention. Mol Cancer Ther 2007, 6:2139-2148.
53. Chautard E, Loubeau G, Tchirkov A, Chassagne J, Vermot-Desroches C,
Morel L, Verrelle P: Akt signaling pathway: a target for radiosensitizing
human malignant glioma. Neuro Oncol 2010, 12:434-443.
54. Chen N, Karantza V: Autophagy as a therapeutic target in cancer. Cancer
Biol Ther 2011, 11:157-168.
55. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P,
Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, Donia M,
Fagone P, Malaponte G, Nicoletti F, Libra M, Milella M, Tafuri A, Bonati A,
Bäsecke J, Cocco L, Evangelisti C, Martelli AM, Montalto G, Cervello M,
McCubrey JA: Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR
pathways in controlling growth and sensitivity to therapy-implications
for cancer and aging. Aging (Albany NY) 2011, 3:192-222.
56. McKenna LB, Zhou GL, Field J: Isoform-specific functions of Akt in cell
motility. Cell Mol Life Sci 2007, 64:2723-2725.
57. Manning BD, Cantley LC: AKT/PKB signaling: navigating downstream. Cell
2007, 129:1261-1274.
58. Hara S, Nakashiro K, Goda H, Hamakawa H: Role of Akt isoforms in HGF-
induced invasive growth of human salivary gland cancer cells. Biochem
Biophys Res Commun 2008, 370:123-128.
59. Dillon RL, Muller WJ: Distinct biological roles for the akt family in
mammary tumor progression. Cancer Res 2010, 70:4260-4264.
60. Mure H, Matsuzaki K, Kitazato KT, Mizobuchi Y, Kuwayama K, Kageji T,
Nagahiro S: Akt2 and Akt3 play a pivotal role in malignant gliomas.
Neuro Oncol 2010, 12:221-232.
61. Zhang J, Han L, Zhang A, Wang Y, Yue X, You Y, Pu P, Kang C: AKT2
expression is associated with glioma malignant progression and
required for cell survival and invasion. Oncol Rep 2010, 24:65-72.
62. Pu P, Kang C, Li J, Jiang H, Cheng J: The effects of antisense AKT2 RNA
on the inhibition of malignant glioma cell growth in vitro and in vivo. J
Neurooncol 2006, 76:1-11.
63. Hammond LA, Eckardt JR, Kuhn JG, Gerson SL, Johnson T, Smith L,
Drengler RL, Campbell E, Weiss GR, Von Hoff DD, Rowinsky EK: A
randomized phase I and pharmacological trial of sequences of 1,3-bis(2-
chloroethyl)-1-nitrosourea and temozolomide in patients with advanced
solid neoplasms. Clin Can Res 2004, 10:1645-1656.
64. Blough MD, Beauchamp DC, Westgate MR, Kelly JJ, Cairncross JG: Effect of
aberrant p53 function on temozolomide sensitivity of glioma cell lines
and brain tumor initiating cells from glioblastoma. J Neurooncol 2011,
102:1-7.
65. Estrugo D, Fischer A, Hess F, Scherthan H, Belka C, Cordes N: Ligand bound
beta1 integrins inhibit procaspase-8 for mediating cell adhesion-
mediated drug and radiation resistance in human leukemia cells. PLoS
One 2007, 23:e269.
66. Walsh JG, Cullen SP, Sheridan C, Lüthi AU, Gerner C, Martin SJ: Executioner
caspase-3 and caspase-7 are functionally distinct proteases. Proc Natl
Acad Sci USA 2008, 105:12815-12819.
67. Lamkanfi M, Kanneganti TD: Caspase-7: a protease involved in apoptosis
and inflammation. Int J Biochem Cell Biol 2010, 42:21-24.
68. Ang C, Guiot MC, Ramanakumar AV, Roberge D, Kavan P: Clinical
significance of molecular biomarkers in glioblastoma. Can J Neurol Sci
2010, 37:625-630.
69. Das P, Puri T, Jha P, Pathak P, Joshi N, Suri V, Sharma MC, Sharma BS,
Mahapatra AK, Suri A, Sarkar C: A clinicopathological and molecular
analysis of glioblastoma multiforme with long-term survival. J Clin
Neurosci 2011, 18:66-70.
70. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV,
Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM,
Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D,
Prados M, Cloughesy TF, Sawyers CL, Mischel PS: Molecular determinants
of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med
2005, 353:2012-2024.
71. Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, Geoffroy FJ,
Arusell R, Kitange G, Jenkins RB, Kugler JW, Morton RF, Rowland KM Jr,
Mischel P, Yong WH, Scheithauer BW, Schiff D, Giannini C, Buckner JC:
Phase I/II trial of erlotinib and temozolomide with radiation therapy in
the treatment of newly diagnosed glioblastoma multiforme: North
Central Cancer Treatment Group Study N0177. J Clin Oncol 2008,
26:5603-5609.
72. Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H,
Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M, Fedoroff A, Sneed PK,
Berger MS, McDermott MW, Parsa AT, Vandenberg S, James CD,
Lamborn KR, Stokoe D, Haas-Kogan DA: Phase II study of erlotinib plus
temozolomide during and after radiation therapy in patients with newly
diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 2009,
27:579-584.
73. Degtyarev M, De Mazière A, Orr C, Lin J, Lee BB, Tien JY, Prior WW, van
Dijk S, Wu H, Gray DC, Davis DP, Stern HM, Murray LJ, Hoeflich KP,
Klumperman J, Friedman LS, Lin K: Akt inhibition promotes autophagy
and sensitizes PTEN-null tumors to lysosomotropic agents. J Cell Biol
2008, 183:101-116.
74. Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J, Greenman C,
Edkins S, Bignell G, Davies H, O’Meara S, Parker A, Avis T, Barthorpe S,
Brackenbury L, Buck G, Butler A, Clements J, Cole J, Dicks E, Forbes S,
Gorton M, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A,
Jones D, Kosmidou V, et al: A hypermutation phenotype and somatic
MSH6 mutations in recurrent human malignant gliomas after alkylator
chemotherapy. Cancer Res 2006, 66:3987-3991.
75. Rocchi P, Jugpal P, So A, Sinneman S, Ettinger S, Fazli L, Nelson C,
Gleave M: Small interference RNA targeting heat-shock protein 27
inhibits the growth of prostatic cell lines and induces apoptosis via
caspase-3 activation in vitro. BJU Int 2006, 98:1082-1089.
76. Kamada M, So A, Muramaki M, Rocchi P, Beraldi E, Gleave M: Hsp27
knockdown using nucleotide-based therapies inhibit tumor growth and
enhance chemotherapy in human bladder cancer cells. Mol Cancer Ther
2007, 6:299-308.
77. Matsui Y, Hadaschik BA, Fazli L, Andersen RJ, Gleave ME, So AI: Intravesical
combination treatment with antisense oligonucleotides targeting heat
shock protein-27 and HTI-286 as a novel strategy for high-grade bladder
cancer. Mol Cancer Ther 2009, 8:2402-2411.
doi:10.1186/1476-4598-11-20
Cite this article as: Schultz et al.: Inhibition of HSP27 alone or in
combination with pAKT inhibition as therapeutic approaches to target
SPARC-induced glioma cell survival. Molecular Cancer 2012 11:20.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Schultz et al. Molecular Cancer 2012, 11:20
http://www.molecular-cancer.com/content/11/1/20
Page 24 of 24
